Compare Sezzle Inc (SEZL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Sezzle Inc trades at $125.02 (market cap $4.32B), while Vertex Pharmaceuticals Incorporated trades at $527.16 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.1× Sezzle Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| SEZL | VRTX | |
|---|---|---|
Market Cap | $4.32B | $134.25B |
Sector | Technology | Health |
52-Week High | $188.55 | $529.65 |
52-Week Low | $50.97 | $376.62 |
Enterprise Value | $4.36B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $125.06, up 5.98% with strong recent earnings performance, beating estimates for three consecutive quarters. The stock shows bearish technical signals despite robust fundamentals including 72.36% gross margins and 30.35% net income margins. Recent Q2 2026 results showed 51.7% revenue growth to $149.7 million with raised full-year guidance, though the stock experienced significant volatility following the report.
The outlook remains positive with analyst consensus target of $158.29 representing 26.6% upside, though elevated valuation multiples and technical weakness present near-term headwinds. Execution on growth initiatives and margin maintenance will be critical for sustained appreciation amid competitive fintech landscape and market volatility risks.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
